Fumitremorgin C | Enzo Life Sciences ALX-350-127-C250 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Fumitremorgin C

catalog :

ALX-350-127-C250

quantity :

250 µg

citations: 10

Reference
Salphati L, Lee L, Pang J, Plise E, Zhang X. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010;38:1422-6 pubmed publisher
Takabe K, Kim R, Allegood J, Mitra P, Ramachandran S, Nagahashi M, et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010;285:10477-86 pubmed publisher
Ma Y, Wink M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010;24:146-9 pubmed publisher
Hauswald S, Duque Afonso J, Wagner M, Schertl F, Lubbert M, Peschel C, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res. 2009;15:3705-15 pubmed publisher
Garimella T, Ross D, Eiseman J, Mondick J, Joseph E, Nakanishi T, et al. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. Cancer Chemother Pharmacol. 2005;55:101-9 pubmed
Plasschaert S, Van Der Kolk D, de Bont E, Kamps W, Morisaki K, Bates S, et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res. 2003;9:5171-7 pubmed
Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem. 2002;277:47980-90 pubmed
Rabindran S, Ross D, Doyle L, Yang W, Greenberger L. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000;60:47-50 pubmed
Rabindran S, He H, Singh M, Brown E, Collins K, Annable T, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 1998;58:5850-8 pubmed
Cui C, Kakeya H, Okada G, Onose R, Osada H. Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo). 1996;49:527-33 pubmed

product information

Product ID :

ALX-350-127

Catalog Number :

ALX-350-127-C250

Product Name :

Fumitremorgin C

Product Type :

Biochemical

Size :

250 µg

list of Pubmed id :

20522663, 20110355, 19548284, 19458058, 15580504, 14613996, 12374800, 10646850, 9865745, 8698634

Product Description :

Mycotoxin. Tremorgenic. Potent and specific inhibitor of the breast cancer resistance protein (BCRP; ABCG2). Reverses multidrug resistance mediated by BCRP and increases cytotoxicity of several anticancer agents in vitro.

ALTnames :

FTC, SM-Q

Purity :

≥96% (HPLC)

Storage :

+4°C